These findings demonstrate roles for inflammasome-dependent, IL-1β responses in the pathogenesis of severe, neutrophilic asthma and that increased NLRP3 activation in severe asthma may be therapeutically targeted to treat severe, T2-low disease. This evidence concerns the gene NLRP3 and asthma.